The t(11;14)(q13;q32) and its molecular counterpart, BCLl rearrangement, are consistent features of mantle cell lymphoma (MCL). Rearrangement is thought to deregulate the nearby CCNDl (BCLl/PRADl) proto-oncogene, a member of the cyclin G, gene family, and thereby t o contribute t o tumorogenesis. We and others have previously shown that the BCLl locus is rearranged in 55% t o 60% of MCL patients and that, on chromosome 11, more than 80% of the breakpoints are localized within a l-kbp DNA segment known as the major translocation cluster (MTCI. We have determined the nuclaotide sequence for a portion of the MTC region, and constructed chromosome 1 l-specific oligonucleotides that were in conjunction with a consensus immunoglobulin (Ig) heavy chain joining region (JH) primer used t o perform the polymerase chain reaction (PCR) t o amplify ALIGNANT NON-HODGKIN'S lymphomas and many other human tumors are often associated with specific chromosome translocations, and experimental evidence indicates that genes located at recumng chromosomal breakpoints are directly involved in tumor pathogenesis.' Furthermore, several of these cytogenetic abnormalities are potentially valuable as diagnostic and prognostic aids. The most frequent translocation in human lymphoma is the t(14;18)(q32;q21)? which can be detected by cytogenetic or molecular analyses in approximately 85% of follicular lymphomas. This translocation juxtaposes the proto-oncogene BCL2, from 18q21, with an immunoglobulin (Ig) heavy chain joining region (JH) segment on the derivative chromosome 14. This results in a BCL2-Ig fusion gene, chimeric transcripts, and transcriptional deregulation of the translocated BCL2.3.4 The chromosome breakpoints are remarkably well focused on chromosome segment 18q21 in two welldefined regions of 500 bp, known as the major and the minor breakpoint regi0ns.4.~ Taking advantage of this situation, several authors have shown that the t(14; 18) can be detected by polymerase chain reaction (PCR) amplification of DNA extracted from fresh tumor cells, frozen tissues, and even from formalin-fixed tissue^.^.^ Moreover, because of its extremely high sensitivity, PCR amplification of the BCL2-Ig junction offers a valuable means of detecting minimal residual disease in follicular non-Hodgkin's lymphomas.
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Mantle cell lymphoma (MCL) represents a clinicopathologically distinct subtype of malignant non-Hodgkin's lymphomas that originates from immature virgin B cell in the primary follicle and mantle zone of peripheral lymphoid It accounts for 5% to 10% of the overall number of malignant non-Hodgkin's lymphomas in adults. The t(l1; 14)(q13;q32) and its molecular counterpart, BCLI rearrangement, are consistent features of this lymphoma subtype.'"I6 As a result of the t(l1; 14), the BCLl locus is juxtaposed to an Ig enhancer sequence located on chromosome 14.'7*'8 The subsequent deregulation of CCNDl (PRADU BCLl), a member of the cyclin GI gene family, is thought to perturb the GI-S transition of the cell cycle and thereby to contribute to tumor de~elopment.l~-~~ Although the chro- t(11;14) chromosomal junctional sequences in DNA from 16 MCL patients with breakpoints in the MTC region. 15 of the 16 breakpoints that occurred at the MTC region were amenable t o PCR detection. The sizes of the amplified bands, the existence or not of a Sac I site in the PCR products, and nucleotide sequencing of the amplified DNA from four patients showed that the breakpoints share a remarkable tendency t o tightly cluster within 300 bp on chromosome 11, some of them occurring at the same nucleotide. On chromosome 14, the breakpoints were localized within the Ig JH. Our findings indicate that a BCLl rearrangement can be detected using this approach in roughly one half of the MCL patients. This has implications for both the diagnosis and the clinical management of MCL. mosome breakpoints are widely scattered on chromosome region 1 lq13, we and others have shown that more than 80% of them are clustered in a restricted DNA segment known as the major translocation cluster (MTC).'3. '5"8.24 In the present study we showed that 15 of the 16 t(l1; 14) breakpoints that occur at the MTC are amenable to PCR detection because they share a remarkable tendency to cluster tightly within 300 bp on chromosome 1 1. These findings should facilitate application of the PCR techniques for the diagnosis and the clinical management of MCL. DNA sequencing of the PCR products. To clone and sequence the amplified DNA, some PCR reactions were performed using oligonucleotides P I P 3 carrying the recognition sequence for EamHI or EcoRI at their 5' ends. The PCR products were eluted from agarose, digested with BamHI and EcoRI and cloned in the Bluescript vector. The inserts were sequenced using the double-stranded DNA sequencing technique (dideoxy chain termination procedure) with sequenase I1 (US Biochemical Corp. Cleveland, OH) as described by the manufacturer.
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RESULTS AND DISCUSSION
The results of BCLl rearrangement analysis for all the samples presented here have been reported in a previously published study.22 In this study, we showed that the BCLl locus was rearranged in 19 of the 33 MCL (57%) patients tested, and that in 16 of them, the breakpoint was in the vicinity of the MTC region. In these 16 cases, no MTC/JH comigration was observed and we assumed that the rearranged fragment detected with the MTC probe was likely to originate from the derivative chromosome 11. To map more accurately the t ( 1 1 ; 14) chromosomal breakpoints, we decided first to clone a probe capable of detecting the rearranged fragment originating from the derivative chromosome 14.
Screening of a genomic DNA library with the MTC probe allowed us to isolate several overlapping recombinant clones containing more than 5 kbp of the region telomeric of MTC (Fig l) . Following restriction endonuclease mapping analysis of this region we were able to isolate an EcoRI-Hind111 DNA fragment (EH04) that is localized 1.5 kbp downstream of MTC (Fig l) . An EH04/JH comigration was observed in all the 16 cases studied here (data not shown). This implied that the EH04 probe detected the rearranged fragments that originate from the derivative chromosome 14 and that, on chromosome 1 1, the breakpoints were localized between the MTC and the EH04 probes. Moreover, as Southern blot analysis using EH04 probe detected a rearranged fragment in HindIII-cleaved DNA but not in EcoRI-digested DNA from 15 of the 16 patients, we were able to narrow the location of the breakpoints within a 2-kbp region delimited by the EcoRI site on the centromeric side. Patient 26 was the only one to show a rearranged band in EcoRI digest with EH04 probe, indicating that in this case, the break occurred in a region telomeric of the EcoRI site. Finally, we had previously noted that, when the breakpoints on chromosome 11 were localized within the Sad-Sac1 fragment which corresponds to the MTC probe, only one rearranged band could be shown in Sac1 digest. This indicated that the breaks, in these cases, might be very close to the MTC telomeric Sac1 site. Added to previous studies, these data clearly showed that the majority of the t ( 1 1 ; 14) breakpoints are focused on a well-defined chromosome 11 region and that they could be so detected by PCR amplification using Ig-and chromosome 1 I-specific primers.
To investigate further this region of chromosome 11 and the translocation breakpoints that were detectable with the MTC and EH04 probes, selected nucleotide sequencing was performed on germline chromosome 11 DNA containing and flanking the MTC and EH04 fragments. The resulting sequence (Fig 2) was used to construct oligonucleotides for use in PCR reaction in combination with a consensus Ig JH primer. These primers were used to study DNA specimens from a set of lymphomas that were selected solely because they had detectable chromosome 11 rearrangements on Southern blots using the MTC probe. When a chromosome 1 l-specific primer (E) was used with the consensus JH primer (PI) on these DNA specimens, 15 of 16 were found to contain amplified DNA bands as detected after ethidium bromide staining of the control gel, or after hybridization of the filters with a radiolabeled oligonucleotide (P3) homologous to the amplified segment of chromosome 1 1. On ethidium bromide stained gel, several faint aspecific bands can be observed in all the samples, but are no longer present after hybridization with the radiolabeled oligonucleotide. Most of the specimens showed two major hybridization bands with P , & '   Fig 3. Analysis of the PCR products. DNAs from each pathologic sample were subjected to PCR using MTC primer p2 and a consensus lg JH primer (Pl) as described in Materials and Methods. Reaction products were electrophoresed through 2% agarose gel. After ethidium bromide staining (top), the gel was transferred onto nylon rnembranes and hybridized with kinased-chromosome 11-specific primer P3 (bottom). T represents the sample without DNA. The scale is in base pairs. different sizes. DNA from normal leucocytes and from patient 26 failed to result in detectable hybridization bands (Fig 3) . This assay was capable of detecting 1 lymphoma cell in lo5 total cells with 1 pg of genomic DNA (data not shown).
After cloning in the Bluescript vector, the PCR products from 4 patients (two patients with a single amplified band and two patients with two amplified bands) were sequenced to determine the precise locations of each breakpoint on chromosome 1 I-DNA. In Fig 4 , the nucleotide sequences of the four chromosomal junctions are compared with the ones of four other t ( 11; 14) previously r e p~r t e d . " .~~.~~ The location of breakpoint sites within germline chromosome 11 DNA are shown as arrows in Fig 2. The data show that all breakpoints occurred within a 75-bp region of chromosome 11 DNA and that some of them occurred at the same nucleotide position. Sequencing of the PCR products also showed that in cases 20 and 25, which showed two amplified bands, the larger one is caused by the annealing of the consensus JH primer not only to the JH segment involved in the translocation, but also to a JH segment immediately centromeric of it (54 and J5 in case 20, JI and 52 in case 25; data not shown). Finally, the sizes of the amplified bands and the presence or not of a Sac I site in the amplified DNA enabled us to determine more accurately the location of 15 of the 16 breakpoints within a 300-bp region as mentioned in Fig 1. Interestingly, this region contains the following nucleotide sequence: GGGAGGACTGT, which represents a potential The relative high GC content of these additional sequences makes them likely to represent N insertions similar to those found at the variable-diversity (V-D) and diversity-joining (D-J) joints of Ig gene. However, we cannot rule out the possibility that some of these sequences actually represent D segments and we are thus unable to confirm that the breakpoints shown here occurred as an error in the D-J or V-D joining reactions. In cases 4 and 20, the absence of an additional sequence between the chromosome 1 1 and 14 sequences suggests that the translocation may result from another mechanism involving, as a possibility, the bp45 protein mentioned above.
The analysis of a large series of MCL had allowed us to show that the BCLl locus is rearranged in 57% of these lymphomas and that in 84% of the BCL1-rearranged MCL, the break on chromosome 1 1 involves the MTC region. In the present study, we show that most (15/16) of the t( 11; 14) breakpoints that occur at the MTC are amenable to PCR detection using Ig-and chromosome 1 l-specific primers and thus, that a BCLl rearrangement can be detected using this approach in roughly one half of the MCL patients.
MCL is a lymphoid malignancy whose histologic recognition and treatment remain problematic. According to the different histologic classifications, MCL is either considered as a low-or intermediate-grade B-cell lymphoma. However, it behaves like an aggressive tumor with a poor response to the chemotherapy regimens used so far, and its median survival is less than 5 years. Because of its simplicity and of its high sensitivity, PCR detection of BCLZ rearrangement in MCL patients provides new perspectives in the diagnosis and the treatment of this disease. In fact, this assay markedly refines the capacity to detect minimal residual disease in MCL patients and should improve the ability to determine the stage of the disease, to stratify treatment, and to evaluate therapy.
Beside MCL, BCL-l rearrangement is also readily detectable in other B-cell malignancies, namely multiple myeloma, plasma cell leukemia and prolymphocytic leukemiaI4 where the incidence of the t ( 1 1; 14) ranges from 5 to 20%. PCR detection of BCL-l rearrangement should also provide guidance for the clinical management of these tumors.
